These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38374618)

  • 41. Victorian Specialist Immunisation Services (VicSIS) - bolstering adult clinics for COVID-19 vaccines.
    Gordon SF; Virah Sawmy E; Duckworth E; Wolthuizen M; Clothier HJ; Chea M; Tenneti N; Blow N; Buttery JP; de Luca J; Korman TM; Barnes S; Slade C; Maggs C; Giles ML; Teh BW; Aboltins C; Langan KM; Van Diemen A; Crawford NW
    Hum Vaccin Immunother; 2022 Nov; 18(5):2052701. PubMed ID: 35471988
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Active SMS-based influenza vaccine safety surveillance in Australian children.
    Pillsbury A; Quinn H; Cashman P; Leeb A; Macartney K;
    Vaccine; 2017 Dec; 35(51):7101-7106. PubMed ID: 29128379
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database.
    Kim MS; Jung SY; Ahn JG; Park SJ; Shoenfeld Y; Kronbichler A; Koyanagi A; Dragioti E; Tizaoui K; Hong SH; Jacob L; Salem JE; Yon DK; Lee SW; Ogino S; Kim H; Kim JH; Excler JL; Marks F; Clemens JD; Eisenhut M; Barnett Y; Butler L; Ilie CP; Shin EC; Il Shin J; Smith L
    J Med Virol; 2022 Mar; 94(3):1085-1095. PubMed ID: 34709664
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network.
    LaRussa PS; Edwards KM; Dekker CL; Klein NP; Halsey NA; Marchant C; Baxter R; Engler RJ; Kissner J; Slade BA
    Pediatrics; 2011 May; 127 Suppl 1():S65-73. PubMed ID: 21502239
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China.
    Hu Y; Pan X; Chen F; Wang Y; Liang H; Shen L; Chen Y; Lv H
    Hum Vaccin Immunother; 2022 Dec; 18(1):2035141. PubMed ID: 35240930
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Consumer reporting of adverse events following immunization (AEFI): identifying predictors of reporting an AEFI.
    Parrella A; Gold M; Braunack-Mayer A; Baghurst P; Marshall H
    Hum Vaccin Immunother; 2014; 10(3):747-54. PubMed ID: 24406315
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine using the national adverse event following immunization surveillance system from Zhejiang province, 2018-2020.
    Hu Y; Pan X; Shen L; Chen F; Wang Y; Liang H; Chen Y; Lv H
    Hum Vaccin Immunother; 2021 Dec; 17(12):5447-5453. PubMed ID: 34613883
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adverse event following vaccine surveillance in Kaduna State, Northwestern Nigeria (January 2018 -June 2019): analysis of health facility´s records.
    Ishaku SG; Umeh G; Adzu B; Onimisi A; Dauda M; Iyal HA; Iliyasu N; Sunday DJ; Daikwo J; Yates SM; Ibrahim II; Samaila LH; Abdullahi B; Parom SK; Maiwashi KY; Zakari F; Nuhu KS
    Pan Afr Med J; 2021; 40():268. PubMed ID: 35251462
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Active surveillance of adverse events after immunization (AEFI) from the Local Health Unitof Ferrara, Italy.
    Marra A; Donzelli A; Florescu C; Rauzino A; Mattei A; Sbarbati MM; Fiasca F; Stefanati A; Gabutti G
    J Prev Med Hyg; 2022 Jun; 63(2):E208-E212. PubMed ID: 35968066
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An evaluation of adverse events following an immunization campaign with the live, attenuated SA14-14-2 Japanese encephalitis vaccine in Cambodia.
    Hills SL; Soeung SC; Sarath S; Morn C; Dara C; Fischer M; Thigpen MC
    PLoS One; 2022; 17(6):e0269480. PubMed ID: 35679297
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands.
    van der Boor SC; Schmitz-de Vries ETJ; Smits D; Scholl JHG; Rolfes L; van Hunsel F
    Vaccine; 2023 Jun; 41(29):4319-4326. PubMed ID: 37286408
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Deaths reported to national surveillance for adverse events following immunization in China, 2010-2015.
    Wu W; Liu D; Nuorti JP; Li K; Xu D; Ye J; Zheng J; Cao L; Wang H
    Vaccine; 2019 Feb; 37(9):1182-1187. PubMed ID: 30709723
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands.
    Kant A; Jansen J; van Balveren L; van Hunsel F
    Drug Saf; 2022 Apr; 45(4):319-331. PubMed ID: 35314943
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China.
    Pan X; Lv H; Liang H; Wang Y; Shen L; Chen F; Chen Y; Hu Y
    Hum Vaccin Immunother; 2022 Dec; 18(1):2021711. PubMed ID: 35108152
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adverse events following immunization: Findings from 2017/2018 measles vaccination campaign, Nigeria AEFI reporting in 2017/2018 measles vaccination campaign.
    Gbenewei E; Nomhwange T; Taiwo L; Ayodeji I; Yusuf K; Jean Baptiste AE; Nsubuga P; Braka F; Oteri J; Shuaib F
    Vaccine; 2021 Nov; 39 Suppl 3():C82-C88. PubMed ID: 33714655
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and adverse events following COVID-19 vaccination among people with epilepsy: A cross-sectional study.
    Ong MJY; Khoo CS; Lee YX; Poongkuntran V; Tang CK; Choong YJ; Hod R; Tan HJ
    Epilepsia Open; 2023 Mar; 8(1):60-76. PubMed ID: 36214033
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adverse event following immunization surveillance systems for pregnant women and their infants: a systematic review.
    Cassidy C; MacDonald NE; Steenbeek A; Top KA
    Pharmacoepidemiol Drug Saf; 2015 Apr; 24(4):361-7. PubMed ID: 25683692
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Real-world safety profile of the 9-valent human papillomavirus vaccine: A study in Zhejiang, China from 2019 to 2021.
    Chen F; Pan X; Liang H; Shen L; Wang Y; Chen Y; Lv H; Hu Y
    Hum Vaccin Immunother; 2022 Dec; 18(7):2152256. PubMed ID: 36484114
    [TBL] [Abstract][Full Text] [Related]  

  • 59. COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study.
    Ferrara F; Mancaniello C; Varriale A; Sorrentino S; Zovi A; Nava E; Trama U; Boccellino M; Vitiello A
    Clin Drug Investig; 2022 Dec; 42(12):1065-1074. PubMed ID: 36274082
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vaccine pharmacovigilance in India: Current context and future perspective.
    Meher BR
    Indian J Pharmacol; 2019; 51(4):243-247. PubMed ID: 31571710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.